Assignee
MAGENTA THERAPEUTICS INC
US·14 granted patents·42 pending applications·57 citations·filing 2014–2023
Top patents by PatentIndex Score
56 records- 0192US10899843B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 26, 2021·8 cites·38 claims
- 0291US10882915B2Compositions and methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·9 cites·27 claims
- 0389US11572411B2Anti-CD117 antibodies and conjugatesMAGENTA THERAPEUTICS INC·Filed 2020·Granted Feb 7, 2023·2 cites·14 claims
- 0489US10351572B2Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2019·Granted Jul 16, 2019·5 cites·28 claims
- 0589US10111966B2Methods for the depletion of CD117+ cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Oct 30, 2018·12 cites·16 claims
- 0686US10058573B1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·7 cites·9 claims
- 0785US11229711B2Linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Jan 25, 2022·3 cites·5 claims
- 0884US10919900B2Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2019·Granted Feb 16, 2021·1 cites·16 claims
- 0984US10781259B2Modified antibodies and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2014·Granted Sep 22, 2020·3 cites·29 claims
- 1084US10624973B2Methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Apr 21, 2020·2 cites·26 claims
- 1181US10457683B2Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·2 cites·20 claims
- 1280US2024207428A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1379US10434185B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·1 cites·29 claims
- 1477US11260079B2Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2019·Granted Mar 1, 2022·1 cites·23 claims
- 1575US10576161B2Compositions and methods for the depletion of CD137+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·1 cites·24 claims
- 1672US2023130646A1Dosing regimens for the mobilization of hematopoietic stem cellsMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1768US2021179625A1Aryl hydrocarbon receptor antagonists and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1867US2020392108A1Antibody-drug conjugates and related compounds, compositions and methodsMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1966US2023109312A1Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of useMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2066US2024075157A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2165US2020376134A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2264US2023414565A1Compositions and methods for treating hematological malignanciesMAGENTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2363US2021162063A1Compositions and methods for the depletion of cd117+ cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2463US2019328901A1Compositions and methods for the depletion of cellsMAGENTA THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2563US2022096559A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2660US2020276326A1Compositions and methods for the depletion of cd5+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2760US2019336536A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2859US2020289664A1Compositions and methods for the depletion of cd137+ cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2956US2023330185A1Methods and compositions for transducing hematopoietic stem and progenitor cells in vivoMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3056US2019167726A1Dosing Regimens for the Mobilization of Hematopoietic Stem CellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3156US2021283267A1Therapeutic methods using antibody drug conjugates (adcs)MAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3256US2022177578A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3356US2022177575A1Anti-cd117 antibodies and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3456US2022175946A1Conditioning methods for gene therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3555US2021379113A1Methods for hematopoietic stem and progenitor cell transplant therapyMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3654US2020376135A1Fc silenced antibody drug conjugates (adcs) and uses thereofMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3754US2023183344A1T-cell bispecific binding proteinsMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3853US2022249683A1T-cell depleting therapiesMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3953US2019134217A1Compositions and methods for the depletion of cd117+ cellsMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4053US2022175944A1Anti-cd117 antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4153US2021260212A1Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4253US2021379033A1Methods of treating cancer with aryl hydrocarbon receptor antagonistsMAGENTA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4352US2022226493A1Anthracycline antibody-drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4452US2023390412A1Compositions and methods for allogeneic transplantationMAGENTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4552US2021095039A1Anti-cd252 antibodies, conjugates, and methods of useMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4652US2022401481A1Dosing regimens for the mobilization of hematopoietic stem and progenitor cellsMAGENTA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4751US2022175951A1Anti-CD45 Antibody Drug Conjugates and Uses ThereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4850US2022177577A1Anti-cd117 antibody drug conjugates and uses thereofMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4950US2022062339A1Use of an anti-cd45 antibody drug conjugate (adc) in cell therapyMAGENTA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5049US2019343885A1Compositions and methods for hematopoietic stem and progenitor cell transplant therapyMAGENTA THERAPEUTICS INC·Filed 2018·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →